Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) ...
A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers ...
Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of ...
The chief medical officer of Genetix Biotherapeutics, formerly known as Bluebird bio, discusses timelines and operational ...
CT Insider on MSN
CT joins national push to open access to million-dollar sickle cell gene therapies through Medicaid
About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.
A view of paintings related to sickle cell on a table as Dominique Goodson, who has sickle cell and advocates for awareness about the disease, takes a phone call in her room at her home in the ...
Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...
13don MSN
A CT hospital is researching genes people might not know they have. Here’s why and the goal.
It is a trait that occurs when a person inherits a single gene for a disease and it impacts 8 to 10 million African Americans ...
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...
Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...
LOS ANGELES (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback